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Abstract 
Cytokine-induced killer (CIK) cells are T lymphocytes expanded ex vivo that are endowed with MHC-
independent tumoricidal activity. We have recently demonstrated, in a preclinical setting, that CIK cells are 
active against autologous bone and soft tissue sarcomas. In particular, CIK cells killed a putative sarcoma 
stem cell population that may underlie disease relapse and chemoresistance. 
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Metastatic recurrent bone sarcomas (BSs) and soft tissue sarcomas (STSs) are unmet clinical challenges. 
Conventional chemotherapies have indeed reached a plateau, and metastatic or unresectable diseases are 
currently considered as incurable.
1,2
 In this setting, clinical relapses and chemoresistance are generally 
attributed to a small subset of cancer cells endowed with stem-like features, which as generically defined 
as “cancer stem cells” (CSCs). The identification, characterization, and targeting of CSCs represent major 
challenges for anticancer therapy.
3
 Although a unique biomarker for CSCs has not yet been identified, 
several molecules exposed on the cell surface such as prominin 1 (PROM1, also known as CD133) and STRO-
1, as well as the re-expression of specific genes including POU class 5 homeobox 1 (POU5F1, also known 
as OCT3 or OCT4), Nanog homeobox (NANOG), and various members of the SOX family, have been 
proposed to identify putative CSCs and allow for their targeting.
4,5
 Immunotherapy, which for a long time 
has been viewed only as a promising strategy for the treatment of solid tumors, has nowadays found its 
way to successful clinical applications.
6,7
 Among multiple immunotherapeutic strategies currently under 
investigation, our group has focused on the use of cytokine-induced killer (CIK) cells. CIK cells are T 
lymphocytes expanded ex vivo that exhibit a mixed T-natural killer (NK)-cells phenotype and are endowed 
with MHC-unrestricted tumoricidal activity, targeting both solid and hematologic malignancies.
8
 
We have recently characterized the ability of CIK cells to kill autologous BS and STS cells in a preclinical 
setting.
9
 Our model was autologous with the intent of accounting as much as possible for intrinsic biological 
variables. Thus, primary sarcoma cultures were generated from fresh surgical biopsies. We could confirm 
that both BS and STS cells express ligands recognized by CIK cells, which efficiently killed autologous 
osteosarcoma, liposarcoma, leiomiosarcoma, gastrointestinal sarcoma, and pleomorphic sarcoma cells in 
vitro. The antitumor activity of CIK cells was confirmed in vivo in a murine tumor xenograft model (Fig. 1). 
In this experimental setup, the adoptive infusion of autologous CIK cells delayed indeed tumor growth and 
resulted in significant reduction of tumor proliferative index. Consistently with other immunotherapeutic 
strategies, objective responses, notably the reduction in tumor mass, induced by CIK cells were not 
dramatic, and could better be appreciated by the significant drop in the tumor proliferative index. This is an 
issue consistently faced when immunotherapeutic regimens are tested in clinical trials. Indeed, dimensional 
parameters such as those employed for Response Evaluation Criteria In Solid Tumors (RECIST) may not be 
the most appropriate approach to appreciate clinical responses to immunotherapy. Thus, new criteria to 
monitor the response of neoplastic lesions to immunotherapy, including metabolic variables assessed by 
positron emission tomography-computer tomography (CT-PET), histological data like the degree of necrosis 
of the tumor proliferation index, and immunological parameters, should be evaluated and possibly 
incorporated into preclinical and clinical evaluations. From our findings we could not conclude on what the 
optimal schedule of administration for CIK cells would be. However, based on available information and 
considering the extremely safe profile of CIK cells, it seems reasonable to hypothesize that multiple 
infusions should be performed to exploit the total number of CIK cells available. The optimal clinical setting 
to employ CIK cells may be represented by patients with minimal residual disease or at high risk of relapse 
upon the surgical resection of metastases. 
 
 
Figure 1. Preclinical model unveiling the activity of cytokine-induced cells against autologous bone sarcoma 
and soft tissue sarcoma. Primary sarcoma cultures were generated from fresh surgical biopsies. Putative 
cancer stem cells (CSCs) were visualized upon the transduction of malignant cells with a lentiviral CSC-
detecting vector encoding the enhanced variant of green fluorescent protein (eGFP) under the control of the 
OCT4 promoter (pRRL.sin.PPT.hOct4.eGFP.Wpre). Patient-derived cytokine-induced killer (CIK) cells were 
active in vitro and in vivo against autologous bone sarcoma (BS) and soft tissue sarcoma (STS) cells, including 
putative CSCs. 
As a further investigational step, we designed a gene-transfer strategy to visualize putative CSCs within BSs 
and STSs and evaluate their susceptibility to the cytotoxic activity of CIKs. To this aim, we employed a 
lentiviral CSC-detecting vector encoding the enhanced variant of green fluorescent protein (eGFP) under 
the control of the OCT4 promoter.
10
 The underlying rationale was that the Oct4 promoter would be active 
only in putative CSCs, which would therefore become green and detectable. By means of this approach, we 
could estimate that putative CSCs are present in variable proportions in BS and STS cell cultures (mean 
14.3%) and express ligands recognized by CIK cells similar to their differentiated counterparts. 
It is important to clarify that putative stemness-associated genes are an intriguing tool to visualize cells 
endowed with stem-like features, but they do not necessarily identify bona fide CSCs, which must be 
characterized by means of adequate functional assays. Indeed, our eGFP
+
 putative CSCs displayed a 
significantly reduced proliferative ability in vitro as compared with their differentiated cells. Serial 
transplantations into animals are currently considered as the most accredited method to uncover the true 
staminal nature of cancer cells as opposed to the presence of “transiently amplifying” cell subsets. From a 
clinical-therapeutic perspective, further experiments are required to explore the degree of 
chemoresistance and the actual role of putative CSCs in tumor relapse. This area of investigation is being 
actively pursued in our laboratory. 
Patient-derived CIK cells killed autologous CSCs in vitro as efficiently as their differentiated counterparts. 
While these data demonstrate the susceptibility of CSCs to CIK cells in vitro, the situation is more complex 
in vivo. We indirectly assessed the activity of CIK cells against sarcoma CSCs in vivo analyzing the residual 
fraction of putative CSCs in tumor samples explanted from mice adoptively treated with CIK cells. In this 
setting, tumors that clinically and histologically responded to immunotherapy failed to manifest a relative 
enrichment in eGFP
+
 putative CSCs, as if they were resistant to CIK cells. This indicates that CIK cells were 
equally capable of killing CSCs and more differentiated malignant cells in vivo. Future studies will have to 
confirm these findings, perhaps exploring the self-renewal and tumorigenic capacity of residual tumor cells 
explanted from animals that underwent immunotherapy. An important issue to be considered when 
targeting CSCs is the possible involvement of non-malignant stem cells, bearing a significant risk of side 
effects. CIK may be advantageous from this angle, as they recognize CSCs based on malignant, rather than 
stem-like, features, an ability that should (at least theoretically) spare normal stem cells from 
immunotherapy. 
If confirmed in additional studies, our findings will endow CIK cells with a new therapeutic value, supporting 
their evaluation in clinical trials enrolling BS and STS patients, either as a single immunotherapeutic 
intervention or combined with conventional treatments. 
Disclosure of Potential Conflicts of Interest 
No potential conflicts of interest were disclosed. 
Notes 
Citation: Sangiolo D, Mesiano G, Gammaitoni L, Aglietta M, Grignani G. Activity of cytokine-induced killer 
cells against bone and soft tissue sarcoma. OncoImmunology 2014; 3:e28269; 10.4161/onci.28269 
 
References 
1. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, Göbel U, Helmke K, Jundt G, Kabisch H, 
et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative 
Osteosarcoma Study Group (COSS) J Clin Oncol. 2005;23:559–68. doi: 10.1200/JCO.2005.04.063.  
2. Casali PG, Blay JY, ESMO/CONTICANET/EUROBONET Consensus Panel of experts Soft tissue sarcomas: ESMO Clinical 
Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol.2010;21(Suppl 5):v198–203. doi: 
10.1093/annonc/mdq209. 
3. Borovski T, De Sousa E Melo F, Vermeulen L, Medema JP. Cancer stem cell niche: the place to be.Cancer 
Res. 2011;71:634–9. doi: 10.1158/0008-5472.CAN-10-3220.  
4. Wirths S, Malenke E, Kluba T, Rieger S, Müller MR, Schleicher S, Hann von Weyhern C, Nagl F, Fend F, Vogel W, et al. 
Shared cell surface marker expression in mesenchymal stem cells and adult sarcomas.Stem Cells Transl 
Med. 2013;2:53–60. doi: 10.5966/sctm.2012-0055.  
5. Kumar SM, Liu S, Lu H, Zhang H, Zhang PJ, Gimotty PA, Guerra M, Guo W, Xu X. Acquired cancer stem cell 
phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31:4898–911. doi: 10.1038/onc.2011.656.  
6. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall 
CL, et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically 
engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011;29:917–24. doi: 10.1200/JCO.2010.32.2537.  
7. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, 
Wunderlich JR, et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-
cell transfer immunotherapy. Clin Cancer Res. 2011;17:4550–7. doi: 10.1158/1078-0432.CCR-11-0116.  
8. Mesiano G, Todorovic M, Gammaitoni L, Leuci V, Giraudo Diego L, Carnevale-Schianca F, Fagioli F, Piacibello W, 
Aglietta M, Sangiolo D. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the 
treatment of solid tumors. Expert Opin Biol Ther. 2012;12:673–84. doi: 10.1517/14712598.2012.675323.  
9. Sangiolo D, Mesiano G, Gammaitoni L, Leuci V, Todorovic M, Giraudo L, Cammarata C, Dell’Aglio C, D’Ambrosio L, 
Pisacane A, et al. Cytokine-induced killer cells eradicate bone and soft-tissue sarcomas.Cancer Res. 2014;74:119–29. 
doi: 10.1158/0008-5472.CAN-13-1559.  
10. Levings PP, McGarry SV, Currie TP, Nickerson DM, McClellan S, Ghivizzani SC, Steindler DA, Gibbs CP. Expression of 
an exogenous human Oct-4 promoter identifies tumor-initiating cells in osteosarcoma.Cancer Res. 2009;69:5648–55. 
doi: 10.1158/0008-5472.CAN-08-3580.  
 
